[Form 4] DiaMedica Therapeutics Inc. Insider Trading Activity

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. (DMAC) filed a Form 4 indicating that 10% owner Richard Jacinto II bought 400,000 voting common shares on 07/23/2025 at $3.50 per share. The filing was submitted on 07/25/2025.

The transaction, coded “P,” was executed indirectly through his NFS/FMTC Roth IRA. Following the purchase, the account holds 4,958,823 DMAC shares. Table II shows no derivative securities activity.

The report was filed by a single reporting person who remains subject to Section 16 obligations and lists indirect ownership of the acquired shares.

Positive

• 400,000 shares purchased on 07/23/2025 at $3.50, totaling approximately $1.4 M.
• Indirect holdings increased to 4,958,823 shares in the Roth IRA.

Negative

• None.

Insights

Securities Analyst

TL;DR: 10% owner’s $1.4 M buy adds 400 K DMAC shares, lifting indirect stake to nearly 5 M—generally viewed as constructive insider activity.

The Form 4 discloses a sizeable open-market purchase (code “P”) at $3.50 per share, totaling roughly $1.4 million. Such accumulation by a 10% owner increases his indirect holdings to 4,958,823 shares, reinforcing alignment with shareholders. No sales or derivative transactions were reported, simplifying the ownership picture. While Form 4s do not provide strategic rationale, the scale of buying, relative to existing stake, is material and tends to be interpreted positively by the market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

JACINTO RICHARD II

(Last) (First) (Middle)

4775 COLLINS AVE

STE 3003

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Shares, no par value per share	07/23/2025		P		400,000	A	$3.5	4,958,823	I	By Roth IRA(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are held by NFS/FMTC Roth IRA FBO Richard Jacinto II, of which Richard Jacinto II is the beneficiary.

	/s/ Richard Jacinto II	07/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many DMAC shares did Richard Jacinto II buy on 07/23/2025?

He purchased 400,000 voting common shares.

What was the purchase price per share in the latest DMAC Form 4?

The shares were bought at $3.50 each.

What is Richard Jacinto II's total ownership after the transaction?

His indirect Roth IRA account now holds 4,958,823 DMAC shares.

Through which account were the DMAC shares acquired?

The acquisition was made via NFS/FMTC Roth IRA FBO Richard Jacinto II.

Were any derivative securities reported in this DMAC Form 4 filing?

No, Table II lists no derivative securities.